Pharmaceutical and Biotechnology Construction Sector Report - UK 2016-2020 Analysis

LONDON, Jan. 25, 2017 /PRNewswire/ -- The 3rd edition of the report 'Pharmaceutical and Biotechnology Construction Sector Report – UK 2016-2020 Analysis' addresses the scale of construction activity in the pharmaceutical and biotechnology industry alongside the key contractors operating in that sector. It also assesses the health of the pharmaceutical industry and whether prospective industry performance is likely to lead to greater levels of capital and construction investment.

Key sections covered:

- Market size and overview – value, market drivers and key issues, R&D and manufacturing activity.
- Construction activity - in the pharmaceutical and biotechnology industries.
- Main manufacturing and R&D facilities – the key centres of the South East, East of England, North West, North East and Scotland.
- Construction capability - major companies involved in the pharmaceutical and biotechnology sectors including contractors, consultants and architects.
- Funding and investment - analysis of Government resource and capital funding for science and research.

Key areas of insight include:

- Analysis of the impact of Brexit on the UK pharmaceutical sector – there are significant issues for the industry including the regulation of medicines, EU clinical trials regulation, EU funding for research, access to R&D facilities, the single market, skills base.
- Leading specialist supply companies to the pharmaceutical industry including: cleanroom design, construction and fit-out; clean and controlled air environments; clean air products; bio-containment and contamination control; validation and maintenance.
- Construction costs and issues in the design of pharmaceutical R&D and manufacturing facilities including legislation, regulatory requirements, containment and environmental issues, cleanroom and laboratory design.
- Detailed analysis of pharmaceutical clusters and centres of excellence in the UK. Many of the UK's biotech firms are located in an area known as 'The Golden Triangle', with the centres of London, Cambridge, Oxford and Stevenage housing the UK's largest biomedical cluster in the UK.
- Review of the main challenges facing the pharmaceutical sector including slowing R&D pipelines, dwindling healthcare budgets, rising costs, impending 'patent cliffs', increased regulatory controls, the influence of the generic drugs market and increased pricing pressures.

Key areas covered in the report include:

MARKET OVERVIEW

- Market definition, size and value, overview of the global pharmaceutical market, overview of the UK pharmaceutical market: biopharmaceuticals; medical technology; digital health; genomics sector.
- Location of UK biopharmaceutical manufacturing and R&D sites.
- Pharmaceutical/biotechnology clusters and centres of excellence: Oxfordshire biocluster; London, Cambridge and Stevenage bioclusters.
- Regional concentration of pharmaceutical manufacturing and R&D: Northwest; East, Southeast and London; Northeast; Scotland.
- Future of pharmaceutical manufacturing operations in the UK.
- Value of pharmaceutical industry to the UK economy: UK trade in pharmaceuticals, sales of pharmaceutical drugs to the NHS.
- Pharmaceutical R&D in the UK: government funding for science R&D (resource & capital funding); pharmaceutical company investment in R&D; R&D pipeline.
- Market drivers and key issues in the pharmaceutical industry: drug patent expirations; generic drugs market; university collaboration with the pharmaceutical industry; tax implications and government legislation; long-term implications of 'brexit' on the UK pharmaceutical industry.

CONSTRUCTION ACTIVITY

- Construction output in the UK pharmaceutical and biotechnology sector, forecast through to 2020, prospects for development in construction within this end use sector.
- Construction in the industrial sector, future prospects in construction output within the sector, key influencing factors, growth in factories and warehouses.
- Capital expenditure in the UK pharmaceutical & biotechnology sectors: R&D capital and manufacturing capital.
- Pharmaceutical construction/development pipeline – confirmed projects to 2020.
- Construction issues in the pharmaceutical industry – construction costs; contamination control issues; clean rooms; containment laboratories; legislation/guidelines/standards for cleanroom construction.
- UK science parks and university innovation campuses.
- UK Enterprise Zones and Catapult Centres.

CONSTRUCTION CAPABILITY

- Leading specialist supply companies to the pharmaceutical industry including: cleanroom design, construction and fit-out; clean and controlled air environments; clean air products; bio-containment and contamination control; validation and maintenance.
- Major engineering construction companies involved in the pharmaceutical and biotechnology sectors including contractors, consultants and architects - capability and project experience.

LEADING PHARMACEUTICAL COMPANIES

- Overview and Pharmaceutical Company League Tables (Global and UK).
- Pharmaceutical company profiles: Abbvie; AstraZeneca; Boehringer Ingelheim; GSK; Johnson & Johnson; Merck; Novartis; Pfizer; Roche; Sanofi.
- Other smaller pharmaceutical/biotechnology companies: biotechnology/therapeutics & diagnostics; biotechnology R&D; pharmaceutical.

Download the full report: https://www.reportbuyer.com/product/4246044/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pharmaceutical-and-biotechnology-construction-sector-report---uk-2016-2020-analysis-300396960.html

SOURCE ReportBuyer